Cargando…

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases

Mutations in GBA1, encoding glucocerebrosidase (GCase), cause Gaucher disease (GD) and are also genetic risks in developing Parkinson’s disease (PD). Currently, the approved therapies are only effective for directly treating visceral symptoms, but not for primary neuronopathic involvement in GD (nGD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiangli, Lin, Yi, Liou, Benjamin, Fu, Wenyu, Jian, Jinlong, Fannin, Venette, Zhang, Wujuan, Setchell, Kenneth D. R., Grabowski, Gregory A., Sun, Ying, Liu, Chuan-ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910439/ https://www.ncbi.nlm.nih.gov/pubmed/36574647 http://dx.doi.org/10.1073/pnas.2210442120

Ejemplares similares

Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency
por: Gaweda-Walerych, Katarzyna, et al.
Publicado: (2021)

Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype
por: Liou, Benjamin, et al.
Publicado: (2019)

The role of progranulin (PGRN) in the modulation of anti-inflammatory response in asthma
por: Pogonowska, Milena, et al.
Publicado: (2019)

PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner
por: Wei, Fanhua, et al.
Publicado: (2014)

Thyrotropin Regulates eNOS Expression in the Endothelium by PGRN Through Akt Pathway
por: Jiang, Fengwei, et al.
Publicado: (2018)

Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice
por: Feng, Tuancheng, et al.
Publicado: (2020)

Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases
por: Saeedi-Boroujeni, Ali, et al.
Publicado: (2023)

Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology
por: Fujita, Kyota, et al.
Publicado: (2018)

GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients
por: Greither, Thomas, et al.
Publicado: (2021)

PGRN exacerbates the progression of non-small cell lung cancer via PI3K/AKT/Bcl-2 antiapoptotic signaling
por: Chen, Sicheng, et al.
Publicado: (2021)

Circulating PGRN Levels Are Increased but Not Associated with Insulin Sensitivity or β-Cell Function in Chinese Obese Children
por: Wang, Fengyun, et al.
Publicado: (2018)

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease
por: Peng, Yanyan, et al.
Publicado: (2021)

Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism
por: Götzl, Julia K, et al.
Publicado: (2019)

Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling
por: Wei, Fanhua, et al.
Publicado: (2019)

Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease
por: Sun, Ying, et al.
Publicado: (2013)

MiR‐29b‐3p promotes chondrocyte apoptosis and facilitates the occurrence and development of osteoarthritis by targeting PGRN
por: Chen, Lingqiang, et al.
Publicado: (2017)

Correction: Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling
por: Wei, Fanhua, et al.
Publicado: (2020)

PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy
por: Zhou, Di, et al.
Publicado: (2019)

Repressor Element 1 Silencing Transcription Factor (REST) Governs Microglia-Like BV2 Cell Migration via Progranulin (PGRN)
por: Yu, Tongya, et al.
Publicado: (2020)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

LncRNA H19/miR-29b-3p/PGRN Axis Promoted Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Acting on Wnt Signaling
por: Ding, Dayong, et al.
Publicado: (2018)

Generation of a novel HEK293 luciferase reporter cell line by CRISPR/Cas9-mediated site-specific integration in the genome to explore the transcriptional regulation of the PGRN gene
por: Li, Yanqing, et al.
Publicado: (2019)

The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD
por: Straniero, Letizia, et al.
Publicado: (2020)

The use of CRISPR to generate a whole-gene humanized MAPT and the examination of P301L and G272V clinical variants, along with the creation of deletion null alleles of ptl-1, pgrn-1 and alfa-1 loci
por: Lins, Jeremy, et al.
Publicado: (2022)

The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
por: Pradas, Eddie, et al.
Publicado: (2023)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency
por: Zhao, Xueheng, et al.
Publicado: (2022)

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
por: Polinski, Nicole K., et al.
Publicado: (2022)

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
por: Yun, Seung Pil, et al.
Publicado: (2018)

Successful treatment of infantile oxysterol 7α-hydroxylase deficiency with oral chenodeoxycholic acid
por: Tang, Yun-Ping, et al.
Publicado: (2021)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology
por: Sun, Ying, et al.
Publicado: (2015)

Neurocalcin Delta Knockout Impairs Adult Neurogenesis Whereas Half Reduction Is Not Pathological
por: Upadhyay, Aaradhita, et al.
Publicado: (2019)

Hepatoprotectant Ursodeoxycholyl Lysophosphatidylethanolamide Increasing Phosphatidylcholine Levels as a Potential Therapy of Acute Liver Injury
por: Chamulitrat, Walee, et al.
Publicado: (2012)

The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
por: García‐Sanz, Patricia, et al.
Publicado: (2020)

Global gene expression profile progression in Gaucher disease mouse models
por: Xu, You-Hai, et al.
Publicado: (2011)

Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes
por: Franco, Rafael, et al.
Publicado: (2018)

Loss of Lipid Carrier ApoE Exacerbates Brain Glial and Inflammatory Responses after Lysosomal GBA1 Inhibition
por: Connolly, Kyle J., et al.
Publicado: (2023)

GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance
por: Granek, Zuzanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_neqr2qir9j08fhchlh5on9m03f